UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 46

Sortiert nach

The role of gut hormones and the hypothalamus in appetite regulation

Endocrine Journal, 2010, Vol.57(5), pp.359-372

2010

Link zum Volltext

Verfügbarkeit prüfen

A glucagon analogue decreases body weight in mice via signalling in the liver

Scientific reports, 2021-11, Vol.11 (1), p.22577-7, Article 22577

2021

Link zum Volltext

Verfügbarkeit prüfen

Investigation of Structure-Activity Relationships of Oxyntomodulin (Oxm) Using Oxm Analogs

Endocrinology (Philadelphia), 2009-04, Vol.150 (4), p.1712-1722

2009

Link zum Volltext

Verfügbarkeit prüfen

Investigating the Glucagon Receptor and Glucagon-Like Peptide 1 Receptor Activity of Oxyntomodulin-Like Analogues in Male Wistar Rats

Current therapeutic research, 2015-12, Vol.77 (C), p.111-115

2015

Link zum Volltext

Verfügbarkeit prüfen

Differentiating constitutional thinness from anorexia nervosa in DSM 5 era

Psychoneuroendocrinology, 2017-10, Vol.84, p.94-100

2017

Link zum Volltext

Verfügbarkeit prüfen

Ghrelin acylation by ghrelin- O-acyltransferase can occur in healthy part of oncological liver in humans

American journal of physiology: Gastrointestinal and liver physiology, 2019-03, Vol.316 (3), p.G366-G371

2019

Link zum Volltext

Verfügbarkeit prüfen

1798-P: Chronic Administration of a Long-Acting Glucagon Analogue Results in Enhanced Insulin Secretory Activity in a Directly-Observed Murine Model

Diabetes (New York, N.Y.), 2020-06, Vol.69 (Supplement_1)

2020

Link zum Volltext

Verfügbarkeit prüfen

Increased food intake with oxyntomodulin analogues

Peptides (New York, N.Y. : 1980), 2015-11, Vol.73, p.95-100

2015

Link zum Volltext

Verfügbarkeit prüfen

57-OR: Combined GLP-1, Oxyntomodulin, and Peptide YY Improves Glycaemia and Body Weight in Obesity and Type 2 Diabetes: A Randomized, Single-Blinded Study

Diabetes (New York, N.Y.), 2019-06, Vol.68 (Supplement_1)

2019

Link zum Volltext

Verfügbarkeit prüfen

Analogs of pancreatic polypeptide and peptide YY with a locked PP-fold structure are biologically active

Peptides (New York, N.Y. : 1980), 2013-01, Vol.39, p.6-10

2013

Link zum Volltext

Verfügbarkeit prüfen

Proglucagon-Derived Peptides Do Not Significantly Affect Acute Exocrine Pancreas in Rats

Pancreas, 2016-08, Vol.45 (7), p.967-973

2016

Link zum Volltext

Verfügbarkeit prüfen

Hypoaminoacidemia underpins glucagon-mediated energy expenditure and weight loss

Cell reports. Medicine, 2022-11, Vol.3 (11), p.100810-100810, Article 100810

2022

Link zum Volltext

Verfügbarkeit prüfen

A role for metalloendopeptidases in the breakdown of the gut hormone, PYY 3-36

Endocrinology (Philadelphia), 2011-12, Vol.152 (12), p.4630-4640

2011

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics, adverse effects and tolerability of a novel analogue of human pancreatic polypeptide, PP 1420

British journal of clinical pharmacology, 2012-02, Vol.73 (2), p.232-239

2012

Link zum Volltext

Verfügbarkeit prüfen

A Role for Metalloendopeptidases in the Breakdown of the Gut Hormone, PYY3–36

Endocrinology (Philadelphia), 2011-12, Vol.152 (12), p.4630-4640

2011

Link zum Volltext

Verfügbarkeit prüfen

Effect of Biased GLP-1/Glucagon Receptor Co-agonists on Insulin Secretion

Diabetes (New York, N.Y.), 2018-07, Vol.67 (Supplement_1)

2018

Link zum Volltext

Verfügbarkeit prüfen

Degradation Paradigm of the Gut Hormone, Pancreatic Polypeptide, by Hepatic and Renal Peptidases

Endocrinology (Philadelphia), 2017-06, Vol.158 (6), p.1755-1765

2017

Link zum Volltext

Verfügbarkeit prüfen

Chronic treatment with glucagon-like peptide-1 and glucagon receptor co-agonist causes weight loss-independent improvements in hepatic steatosis in mice with diet-induced obesity

Biomedicine & pharmacotherapy, 2024-07, Vol.176, p.116888, Article 116888

2024

Link zum Volltext

Verfügbarkeit prüfen

Disconnect between signalling potency and in vivo efficacy of pharmacokinetically optimised biased glucagon-like peptide-1 receptor agonists

Molecular metabolism (Germany), 2020-07, Vol.37, p.100991, Article 100991

2020

Link zum Volltext

Verfügbarkeit prüfen

Divergent trajectories of cellular bioenergetics, intermediary metabolism and systemic redox status in survivors and non-survivors of critical illness

Redox biology, 2021-05, Vol.41, p.101907-101907, Article 101907

2021

Link zum Volltext

Verfügbarkeit prüfen

The Effect of a Subcutaneous Infusion of GLP-1, OXM, and PYY on Energy Intake and Expenditure in Obese Volunteers

The journal of clinical endocrinology and metabolism, 2017-07, Vol.102 (7), p.2364-2372

2017

Link zum Volltext

Verfügbarkeit prüfen

Coinfusion of low-dose GLP-1 and glucagon in man results in a reduction in food intake

Diabetes (New York, N.Y.), 2014-11, Vol.63 (11), p.3711-3720

2014

Link zum Volltext

Verfügbarkeit prüfen

Abolishing β‐arrestin recruitment is necessary for the full metabolic benefits of G protein‐biased glucagon‐like peptide‐1 receptor agonists

Diabetes, obesity & metabolism, 2024-01, Vol.26 (1), p.65-77

2024

Link zum Volltext

Verfügbarkeit prüfen

The Metabolomic Effects of Tripeptide Gut Hormone Infusion Compared to Roux-en-Y Gastric Bypass and Caloric Restriction

The journal of clinical endocrinology and metabolism, 2022-02, Vol.107 (2), p.e767-e782

2022

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 46

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(42)
Mit Volltextzugriff
(44)

Publikationsform

Artikel
(45)
Dissertationen
(1)

Sprache

Englisch
(46)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

The role of gut hormones and the hypothalamus in appetite regulation

A glucagon analogue decreases body weight in mice via signalling in the liver

Investigation of Structure-Activity Relationships of Oxyntomodulin (Oxm) Using Oxm Analogs

Investigating the Glucagon Receptor and Glucagon-Like Peptide 1 Receptor Activity of Oxyntomodulin-Like Analogues in Male Wistar Rats

Differentiating constitutional thinness from anorexia nervosa in DSM 5 era

Ghrelin acylation by ghrelin- O-acyltransferase can occur in healthy part of oncological liver in humans

1798-P: Chronic Administration of a Long-Acting Glucagon Analogue Results in Enhanced Insulin Secretory Activity in a Directly-Observed Murine Model

Increased food intake with oxyntomodulin analogues

57-OR: Combined GLP-1, Oxyntomodulin, and Peptide YY Improves Glycaemia and Body Weight in Obesity and Type 2 Diabetes: A Randomized, Single-Blinded Study

Analogs of pancreatic polypeptide and peptide YY with a locked PP-fold structure are biologically active

Proglucagon-Derived Peptides Do Not Significantly Affect Acute Exocrine Pancreas in Rats

Hypoaminoacidemia underpins glucagon-mediated energy expenditure and weight loss

A role for metalloendopeptidases in the breakdown of the gut hormone, PYY 3-36

Pharmacokinetics, adverse effects and tolerability of a novel analogue of human pancreatic polypeptide, PP 1420

A Role for Metalloendopeptidases in the Breakdown of the Gut Hormone, PYY3–36

Effect of Biased GLP-1/Glucagon Receptor Co-agonists on Insulin Secretion

Degradation Paradigm of the Gut Hormone, Pancreatic Polypeptide, by Hepatic and Renal Peptidases

Chronic treatment with glucagon-like peptide-1 and glucagon receptor co-agonist causes weight loss-independent improvements in hepatic steatosis in mice with diet-induced obesity

Disconnect between signalling potency and in vivo efficacy of pharmacokinetically optimised biased glucagon-like peptide-1 receptor agonists

Divergent trajectories of cellular bioenergetics, intermediary metabolism and systemic redox status in survivors and non-survivors of critical illness

The Effect of a Subcutaneous Infusion of GLP-1, OXM, and PYY on Energy Intake and Expenditure in Obese Volunteers

Combined GLP-1, Oxyntomodulin, and Peptide YY Improves Body Weight and Glycemia in Obesity and Prediabetes/Type 2 Diabetes: A Randomized, Single-Blinded, Placebo-Controlled Study

Coinfusion of low-dose GLP-1 and glucagon in man results in a reduction in food intake

Abolishing β‐arrestin recruitment is necessary for the full metabolic benefits of G protein‐biased glucagon‐like peptide‐1 receptor agonists

The Metabolomic Effects of Tripeptide Gut Hormone Infusion Compared to Roux-en-Y Gastric Bypass and Caloric Restriction

Suchergebnisse filtern